NCT06437171View on ClinicalTrials.gov

FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 3, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
Food Allergy
Interventions
BIOLOGICAL

Omalizumab

Omalizumab dose and frequency based on baseline subject weight and total IgE

Trial Locations (1)

33134

AAADRS Clinical Research Center, Coral Gables

Sponsors
All Listed Sponsors
lead

AAADRS Clinical Research Center

OTHER